Science Explorer Back to mapMap
Discussion
Researcher · Synthego (United States) · United States

Jan Emmerich

Jan Emmerich publishes mostly in Oncology, Immunology and Rheumatology, on topics such as CAR-T cell therapy research, Immune Cell Function and Interaction and Immunotherapy and Immune Responses.

ORCID 0000-0002-7216-2231 OpenAlex
World rank
#2,233,418
of 7,710,434 ranked researchers
Rank in United States
#668,789
of 1,627,098
Works
48
Citations
2.1k
Citations per work
44.7
h-index
12
i10-index 12Top 48% in Oncology
Jan Emmerich

What does Jan Emmerich research?

Jan Emmerich's work is mostly in Medicine (32%), Immunology and Microbiology (19%), Biochemistry, Genetics and Molecular Biology (9%).

Everything else: 19 works · 40.4% of their workHealth Sciences: 15 works · 31.5% of their workMedicine: 15 works · 31.5% of their workOncology: 10 works · 20.7% of their workRheumatology: 3 works · 5.8% of their workPulmonary and Respiratory Medicine: 2 works · 5.0% of their workLife Sciences: 13 works · 28.1% of their workImmunology and Microbiology: 9 works · 19.0% of their workImmunology: 9 works · 19.0% of their workBiochemistry, Genetics and Molecular Biology: 4 works · 9.1% of their workMolecular Biology: 2 works · 5.0% of their workCell Biology: 2 works · 4.1% of their workTHEIR WORKJan Emmerich48works
Life Sciences28%Health Sciences32%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else1940.4%
    1. Medicine1531.5%
    1. Immunology and Microbiology919.0%
    2. Biochemistry, Genetics and Molecular Biology49.1%
  1. 1Oncology21% of their works
  2. 2Immunology19% of their works
  3. 3Rheumatology6% of their works
  4. 4Pulmonary and Respiratory Medicine5% of their works
  5. 5Molecular Biology5% of their works
  6. 6Cell Biology4% of their works

Research topics

Which keywords describe Jan Emmerich's research?

The keywords of their largest research topics: Cancer Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Natural Killer Cells, NK Cell Recognition, Dendritic Cells, Immune Checkpoint Blockade and Immunity.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Cancer Immunotherapy212 topics
  2. CAR T Cells131 topic
  3. Chimeric Antigen Receptor131 topic
  4. NK Cell Recognition101 topic
  5. Natural Killer Cells101 topic
  6. Dendritic Cells81 topic
  7. Immune Checkpoint Blockade81 topic
  8. Immunity81 topic
  9. PD-1 and PD-L181 topic
  10. Cardiorespiratory Fitness41 topic
  11. Exercise Capacity41 topic
  12. Foxp331 topic
  13. Mammalian Cells31 topic
  14. Myofascial Trigger Points31 topic
  15. Pain Management31 topic
  16. Recombinant Protein31 topic
  17. TGF-ß31 topic

Where does Jan Emmerich work?

Jan Emmerich's main affiliation in the publication record is Synthego (United States), United States.

How many publications and citations does Jan Emmerich have?

OpenAlex counts 48 works and 2,147 citations for Jan Emmerich, an h-index of 12, ranking #2,233,418 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Jan Emmerich. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.